Related Experiment Video
Updated: Sep 24, 2025
DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Chitosan Modification-Enhanced Silencing Effect of Ad5-shPDGF-D Vector in Breast Cancer Cell Line MDA-MB-231
Ceyda Ekentok-Atıcı1, Jülide Akbuğa2
1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey.
Background:
Gene therapeutics are being developed to treat metastatic breast tumors, which are mostly resistant to conventional therapies. Targeting platelet-derived growth factor-D (PDGF-D) is a viable approach because it is known to play roles in angiogenesis and tumor growth. The success of gene therapy is largely dependent on delivery vectors, but both viral and nonviral delivery vectors have their disadvantages. Evolving hybrid vectors are being used to overcome those disadvantages.
Objectives:
In this study, we aimed to prepare a recombinant adenovirus type-5 (Ad5)/chitosan hybrid vector to deliver shPDGF-D in a breast cancer cell line by the noncovalent coating of the Ad5 surface with chitosan, a natural polymer.
Methods:
The Ad5/chitosan hybrid vector was prepared by the noncovalent coating of the Ad5 surface with different molecular weights (low and high) and different amounts of chitosan (12.5, 25, and 50 μg), and the effect of silencing PDGF-D was investigated in the MDA-MB-231 cell line.
Results:
In vitro characterization studies showed that the noncovalent chitosan coating increased the size of the Ad5 particle and changed the surface charge from -16.53 mV to slightly neutral. In vitro cell culture studies also showed that the addition of chitosan with both low (73.61%) and high (65.86%) molecular weight increased the PDGF-D silencing efficiency of the Ad5 vector (42.44%) at 48 hours. While low-molecular-weight chitosan had faster effects, high-molecular-weight chitosan provided a more sustained effect in PDGF-D silencing.
Conclusion:
The results indicate that noncovalent chitosan modification may improve the therapeutic effects of the Ad5 vector, offering the potential for further in vitro and in vivo experiments.
Insights
This study developed a novel adenovirus type-5 (Ad5)/chitosan hybrid vector for gene therapy in breast cancer. The hybrid vector enhanced the silencing of platelet-derived growth factor-D (PDGF-D), showing potential for improved therapeutic outcomes.
Area of Science:
- Biotechnology
- Gene Therapy
- Nanomedicine
Background:
- Metastatic breast tumors often resist conventional treatments, necessitating novel therapeutic strategies.
- Platelet-derived growth factor-D (PDGF-D) is a key target due to its role in tumor angiogenesis and growth.
- Developing effective delivery vectors is crucial for gene therapy success, as viral and nonviral methods have limitations.
Purpose of the Study:
- To create a recombinant adenovirus type-5 (Ad5)/chitosan hybrid vector for delivering short hairpin RNA targeting PDGF-D (shPDGF-D).
- To investigate the noncovalent coating of Ad5 with chitosan for enhanced gene delivery in a breast cancer cell line.
Main Methods:
- Prepared Ad5/chitosan hybrid vectors using different molecular weights and amounts of chitosan.
- Coated Ad5 particles noncovalently with chitosan.
- Evaluated PDGF-D silencing efficiency in MDA-MB-231 breast cancer cells.
Main Results:
- Chitosan coating modified Ad5 particle size and surface charge.
- Both low and high molecular weight chitosan improved PDGF-D silencing efficiency compared to Ad5 alone.
- Low-molecular-weight chitosan offered faster silencing, while high-molecular-weight chitosan provided sustained silencing.
Conclusions:
- Noncovalent modification of Ad5 with chitosan enhances its gene silencing capabilities.
- This hybrid vector shows promise for improving therapeutic efficacy in breast cancer gene therapy.
- Further in vitro and in vivo studies are warranted to explore the full therapeutic potential.
